2017-2019

Peer-reviewed Publications

  1. Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA; EMPA-HEART CardioLink-6 Investigators. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019 Nov 19;140(21):1693-1702.
  2. Hess DA, Terenzi DC, Trac JZ, Quan A, Mason T, Al-Omran M, Bhatt DL, Dhingra N, Rotstein OD, Leiter LA, Zinman B, Sabongui S, Yan AT, Teoh H, Mazer CD, Connelly KA, Verma S. SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab. 2019 Oct 1;30(4):609-613.
  3. Garg V, Peterson MD, Chu MWA, Ouzounian M, MacArthur RGG, Bozinovski J, El-Hamamsy I, Chu FV, Garg A, Hall J, Thorpe KE, Dhingra N, Teoh H, Marotta TR, Latter DA, Quan A, Mamdani M, Juni P, Mazer CD, Verma S. Axillary versus Innominate Artery Cannulation for Antegrade Cerebral Perfusion in Aortic Surgery: Design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 Randomised Trial. BMJ Open. 2017 Jun 10;7(6):e014491.
  4. Chan V, Chu MWA, Leong-Poi H, Latter DA, Hall J, Thorpe KE, de Varennes BE, Quan A, Tsang W, Dhingra N, Yared K, Teoh H, Chu FV, Chan K-L, Mesana TG, Connelly KA, Ruel M, Jüni P, Mazer CD, Verma S. Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial). BMJ Open. 2017 May 30;7(5):e015032.

Conference Abstracts

  1. Mazer CD, Hare GMT, Connelly PW, Zuo F, Gilbert RE, Shehata N, Quan A, Teoh H, Leiter LA, Zinman B, Jüni P, Thorpe KE, Yan AT, Connelly KA, Verma S. Effect of empagliflozin on erythropoietin levels and red blood cell morphology in patients with type 2 diabetes and coronary artery disease.
    American Heart Association Annual Scientific Sessions. Philadelphia, PA, USA. November 16-18, 2019.
    Circulation. 2019;140(Suppl 1):A11655.
  2. Mason T, Verma S, Yan AT, Chowdhury B, Zuo F, Thorpe K, Coelho-Filho OR, Jerosch-Herold M, Leiter LA, Zinman B, Jüni P, Quan A, Teoh H, Mazer CD, Connelly KA. The effect of empagliflozin on myocardial extracellular matrix expansion in patients with type 2 diabetes and coronary artery disease.
    American Heart Association Annual Scientific Sessions. Philadelphia, PA, USA. November 16-18, 2019.
    Circulation. 2019;140(Suppl 1):A13456.
  3. Bami K, Gandhi S, Leong-Poi H, Yan AT, Ho EC, Zahrani M, Zuo F, Garg V, Teoh H, Quan A, Leiter LA, Zinman B, Mazer CD, Verma S, Ong G, Connelly KA. Effects of Empagliflozin on Diastolic Function in Patients with Type 2 Diabetes Mellitus.
    Annual Meeting of the Canadian Cardiovascular Society, Montreal, Quebec, Canada, October 24-27, 2019.
    Can J Cardiol. 2019; 35 (10 Suppl): S79.
  4. Terenzi DC, Verma S, Trac JZ, Quan A, Mason T, Al-Omran M, Dhingra N, Leiter LA, Zinman B, Yan AT, Connelly KA, Teoh H, Mazer CD, Hess DA. A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and established cardiovascular disease: A sub-study of the EMPA-HEART CardioLink-6 Trial.
    Annual Meeting of the Canadian Cardiovascular Society, Montreal, Quebec, Canada, October 24-27, 2019.
    Can J Cardiol. 2019; 35 (10 Suppl): S77.
  5. Opingari E, Verma S, Mazer CD, Connelly KA, Yan AT, Zuo F, Mason T, Chowdhury B, Pan Y, Quan A, Teoh H, Leiter LA, Zinman B, Cherney DZI, Gilbert RE. Tubular protection with empagliflozin treatment in subjects with type 2 diabetes and cardiovascular disease: a sub-analysis of the EMPA-HEART CardioLink-6 trial.
    Annual Meeting of the European Association for the Study of Diabetes. Barcelona, Spain. September 16-20, 2019.
    Diabetologia. 2019; 62 (Suppl 1): S330. Abstract 690.
  6. Garg V, Verma S, Connelly KA, Yan AT, Sikand A, Garg A, Dorian P, Zuo F, Leiter LA, Zinman B, Juni P, Verma A, Quan A, Mazer CD, Ha ACT. Does empagliflozin modulate the autonomic system among patients with type 2 diabetes and coronary artery disease? Insights from the Holter substudy of the EMPA-Heart CardioLink-6 Randomised Trial.
    European Society of Cardiology Congress. Paris, France. August 31-September 4, 2019.
    Eur Heart J. 2019; 40(Suppl 1): 2351 Abstract: P3753.
  7. Garg V, Verma S, Peterson MD, Chu MWA, Quan A, Zuo F, Teoh H, Mazer CD, Smith EE. Comparison of innominate vs axillary artery cannulation for cerebral protection on neurocognitive outcomes in aortic surgery: a prespecified analysis of the ACE CardioLink-3 randomised trial.
    European Society of Cardiology Congress. Paris, France. August 31-September 4, 2019.
    Eur Heart J. 2019; 40: 3474 Abstract: P5602.
  8. Bami K, Gandhi S, Leong­Poi H, Yan A, Ho E, Zahrani M, Garg V, Teoh H, Quan A, Mazer D, Verma S, Ong G, Connelly. Effects of empagliflozin on cardiac function in patients with type 2 diabetes mellitus: echocardiographic substudy of the EMPA­HEART CardioLink­6 trial.
    European Society of Cardiology Congress. Paris, France. August 31-September 4, 2019.
    Eur Heart J. 2019; 40(Suppl 1): 806 Abstract: P1500.
  9. Terenzi DC, Verma S, Trac JZ, Quan A, Mason T, Al-Omran M, Dhingra N, Leiter LA, Zinman, Yan AT, Connelly KA, Teoh H, Mazer CD, Hess DA. A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A substudy of the EMPA-HEART CardioLink-6 Trial.
    European Society of Cardiology Congress. Paris, France. August 31-September 4, 2019.
    Eur Heart J. 2019; 40(Suppl 1): 115 Abstract: P317.
  10. Peterson MD, Garg V, Mazer CD, Chu MWA, Bozinovski J, Dagenais F, MacArthur RGG, Moon MC, Ouzounian M, Quan A, Khan MN, Saad F, Gupta N, Mamdani M, Jüni P, Latter DA, Bhatt DL, Marotta TR, Floyd TF, Fedak PWM, Bharatha A, Hall J, Nadamalavan D, Al-Omran M, Dickson J, Teoh H, Thorpe KE, Dai DWH, Smith EE, Verma S. Brain Protection for Aortic Arch Surgery: Axillary vs. Innominate Artery Cannulation for Cerebral Protection – Results of the ACE Randomized Clinical Trial.
    Annual Meeting of the American Association for Thoracic Surgery. May 4-7, 2019. Toronto, Ontario, Canada.
  11. Verma S, Mazer CD, Yan AT, Mason T, Slabiak A, Bello OO, Opingari E, Fitchett DH, Goldenberg RM, Goodman SG, Farkouh ME, Partridge A, Bonneau C, Bakbak E, Dhingra N, Williams AH, Lambotharan SG, Gupta N, Chowdhury B, Dai DWH, Jüni P, Teoh H, Quan A, Liuni A, Leiter LA, Bhatt DL, Zinman B, Connelly KA, EMPA-HEART Investigators. EMPA-HEART CardioLink-6 Trial: A randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes (T2D) and coronary heart disease.
    American Heart Association Annual Scientific Sessions. Chicago, IL, USA. November 10-12, 2018.
    Circulation. 2018;138:e762: 19332.
© 2024 CardioLink Canada. All rights reserved